CenTrial Logo

Breakthrough Treatment for Osteoporosis in Men: Abaloparatide-SC


Clinical trial confirms abaloparatide-sc can improve bone density in men with osteoporosis

Osteoporosis is a condition that weakens our bones and makes them more prone to fractures. It is commonly associated with older women, but did you know that men can also develop osteoporosis?

The word osteoporosis means ‘porous bone’. It is a condition characterized by excessive bone breakdown and inadequate new bone formation resulting in weak spongy bones that are at a greater risk of pathological fractures.

Postmenopausal women are typically affected by this condition however, osteoporosis in men is an important but underappreciated public health problem. Approximately one in four men over 50 years of age will incur a fragility fracture in their lifetime, with men accounting for up to 30% of the societal burden of osteoporosis and fractures.

Abaloparatide-SC is a medication designed to strengthen bones in individuals with osteoporosis. It belongs to a class of drugs called parathyroid hormone-related protein analogs. This treatment has already shown significant benefits in women with osteoporosis, but its effects in osteoporotic men are yet to be determined.

Clinical Trial
A clinical trial conducted by a team of scientists has uncovered a promising treatment called Abaloparatide-SC that can potentially improve the bone health of men suffering from osteoporosis. The trial involved 228 men aged 40 to 85 years suffering from osteoporosis. Of these, 149 participants received daily subcutaneous injections of abaloparatide 80 μg for 12 months while 79 participants received a placebo (a clinically ineffective drug) during this period.

The changes in bone mineral density (BMD) of the lumbar spine, hip, and femoral neck were measured at the end of 12 months of treatment.

The results of the clinical trial were very promising. The researchers found that men who received Abaloparatide-SC experienced a significant increase in bone mineral density (BMD) compared to those who received the placebo.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
Bone mineral density is an important measure of bone strength and health. By increasing BMD, Abaloparatide-SC can help reduce the risk of fractures and improve overall bone health.

Not only did Abaloparatide-SC increase bone mineral density, but it also reduced the incidence of new fractures in men with osteoporosis. In the abaloparatide group, there was one new clinical fracture (forearm) and in the placebo group, there were three patients with a new clinical fracture (spine, clavicle, and knee).

Safety of Abaloparatide-SC
Ensuring the safety of any medication is of utmost importance. In this study, Abaloparatide-SC demonstrated a favorable safety profile. The most common treatment-emergent adverse events were injection site reaction, dizziness, nasopharyngitis, arthralgia, bronchitis, hypertension, and headache. However, these side effects were generally well-tolerated and did not cause significant issues for the participants.

The ATOM clinical trial has shown remarkable results of abaloparatide use in osteoporotic men. This medication has been proven to increase bone mineral density and reduce the risk of new fractures. Furthermore, it has exhibited a favorable safety profile, with mild and well-tolerated side effects.
This breakthrough treatment offers hope for men suffering from osteoporosis, providing them with a potential solution to improve their bone health and overall quality of life.
Journal of Bone and Mineral Research, Oct-03-22

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Without participants there can be no clinical trials.
Without clinical trials there will be no new treatments.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.